← Back to patent-cliff list
CAS 1225062-32-7
Codes: BERZO-004
Application context (from source-drug indications)
LeiomyosarcomaBerzosertibNeuroendocrine tumourBerzosertibSolid tumourBerzosertibLung cancerBerzosertibSquamous cell carcinomaBerzosertibSmall cell lung cancerBerzosertib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Berzosertib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
3,5-dibromopyrazin-2-amine→ethynyltrimethylsilane→5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine→BERZO-004→(4-(isopropylsulfonyl)phenyl)boronic acid→BERZO-006→(Z)-N-hydroxy-4-methylbenzimidoyl chloride→BERZO-008→BERZO-009→5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.